The phase I RELEASE clinical trial to evaluate the safety of NK cells in COVID-19

The phase I RELEASE clinical trial to evaluate the safety of NK cells in COVID-19

Summary: The severity of COVID 19 symptoms has a direct correlation with lymphopenia, affecting natural killer (NK) cells. SARS-CoV-2 specific “memory” NK cells obtained from convalescent donors can be used as cell immunotherapy. In 2022 a phase I, dose-escalation, single center clinical trial was c...

Full description

Saved in:
Bibliographic Details
Main Authors: Clara Hernández-Blanco, Karima Al-Akioui-Sanz, Lara Herrera, Cristina Aguirre-Portolés, Daniel Lozano-Ojalvo, Leticia Pérez-Rodriguez, Jordi Cano-Ochando, Pilar Guerra-García, Alejandro Martín-Quirós, José Luis Vicario, Silvia Santos, Miguel Ángel Pérez-Vaquero, Miguel Ángel Vesga, Alberto M. Borobia, Antonio J. Carcas, Antonio Balas, Miguel Ángel Moreno, Rebeca Pérez de Diego, Mercedes Gasior, Bernat Soria, Cristina Eguizabal, Antonio Pérez-Martínez
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:iScience
Subjects:
Immunology
Cell biology
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004224029250
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2589004224029250

Similar Items